Elsten Syrup (Erdosteine)

Adult dose

Adults: Administer 350 mg orally per dose twice daily.

Child dose

Body weight 15～19 ㎏: Administer 175 mg orally per dose twice daily. Body weight 20～30 ㎏: Administer 175 mg orally per dose 3 times daily. Children weighing 30 ㎏ or more: Administer 350 mg orally per dose twice daily.

This medication contains aspartame, an artificial sweetener that is metabolized into phenylalanine in the body. Therefore, it should not be used by patients with the hereditary disease phenylketonuria. The acceptable daily intake of aspartame is limited to 40mg per kg of body weight according to WHO recommendations, and a 60kg adult can take up to a maximum of 2.4g per day. This medication should not be administered to certain patients. For example, those who are allergic to this medication or its components, patients with liver cirrhosis, and those with cystathionine synthase deficiency should not use this medication. Additionally, patients with peptic ulcers, severe kidney impairment, and severe liver dysfunction should avoid taking this medication. Since this medication contains lactose, individuals with lactose intolerance or related genetic disorders should also refrain from using it. Patients with mild to moderate liver function should use this medication cautiously and should avoid exceeding a dose of 300mg per day. Diabetic patients or those on a low-calorie diet should be particularly cautious when taking the syrup formulation. Overdose of this medication may result in symptoms such as sweating, dizziness, and flushing. Gastrointestinal symptoms such as headaches, cold symptoms, shortness of breath, taste disturbances, nausea, vomiting, diarrhea, abdominal pain, and heartburn have also been reported. Skin reactions such as urticaria, erythema, and eczema may occur. Various adverse reactions including fatigue, dyspepsia, palpitations, and facial swelling have been reported in domestic post-marketing studies, though a direct correlation with this medication is not clearly established. Caution is required when taking this medication in combination with expectorants, as it may make mucus expulsion difficult and increase the risk of bronchial infection and bronchospasm. Pregnant or breastfeeding women should avoid using this medication, as its safety has not been sufficiently established. This medication should be kept out of the reach of children, and transferring it to another container should be avoided to maintain quality and prevent safety incidents.

• sweating
• dizziness
• flushing
• headache
• cold
• difficulty breathing
• taste disorder
• nausea
• vomiting
• diarrhea

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is important to maintain storage temperatures between 1 and 30 degrees Celsius.

Appearance

This medication is a white crystalline powder with a strawberry flavor and taste that is formulated as a syrup to be suspended in water before use. When suspended in water, it forms a white to pale yellow suspension.

Package unit

25g (when solvent is added 50mL)/bottle X 10